[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 340,541
  • Shares Outstanding, K 53,883
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,770 K
  • EBIT $ -34 M
  • EBITDA $ -35 M
  • 60-Month Beta 0.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.45

Options Overview Details

View History
  • Implied Volatility 225.51% (+113.10%)
  • Historical Volatility 46.20%
  • IV Percentile 69%
  • IV Rank 32.64%
  • IV High 518.38% on 07/14/25
  • IV Low 83.60% on 12/17/25
  • Expected Move (DTE 4) 1.11 (17.13%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 600
  • Open Int (30-Day) 1,261
  • Expected Range 5.35 to 7.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 1
  • High Estimate $-0.18
  • Low Estimate $-0.18
  • Prior Year $-0.18
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.80 +11.21%
on 04/13/26
7.05 -8.45%
on 04/17/26
+0.46 (+7.68%)
since 04/10/26
3-Month
5.71 +12.96%
on 04/10/26
9.04 -28.65%
on 02/13/26
-1.85 (-22.29%)
since 02/11/26
52-Week
3.47 +85.61%
on 07/02/25
10.42 -38.10%
on 12/10/25
+2.79 (+76.23%)
since 05/09/25

Most Recent Stories

More News
DiaMedica Therapeutics Q1 Earnings Call Highlights

DiaMedica Therapeutics (NASDAQ:DMAC) executives outlined progress across the company’s DM199 clinical programs in preeclampsia and acute ischemic stroke during the company’s first-quarter 2026 earnings...

DMAC : 6.45 (+2.06%)
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ...

DMAC : 6.45 (+2.06%)
DMAC's Preeclampsia Bet May Already Be Priced Into Eighteen-Cent Loss Estimate

Barchart Research What to Expect from DMAC Earnings DMAC Generated May 5, 2026 Current Price $6.24 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 7.15% DMAC's Preeclampsia Bet May Already...

DMAC : 6.45 (+2.06%)
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS),...

DMAC : 6.45 (+2.06%)
RedChip's Biotech Virtual Investor Conference Replays Now Available

ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

CLDI : 0.1985 (-5.70%)
INAB : 1.6250 (+2.85%)
DMAC : 6.45 (+2.06%)
NSRX : 3.04 (-3.49%)
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

CLDI : 0.1985 (-5.70%)
INAB : 1.6250 (+2.85%)
CNTB : 2.34 (-0.85%)
DMAC : 6.45 (+2.06%)
NSRX : 3.04 (-3.49%)
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199...

DMAC : 6.45 (+2.06%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends.

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 6.45 (+2.06%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends.

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 6.45 (+2.06%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends.

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 6.45 (+2.06%)

Business Summary

DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada....

See More

Key Turning Points

3rd Resistance Point 7.00
2nd Resistance Point 6.82
1st Resistance Point 6.63
Last Price 6.45
1st Support Level 6.26
2nd Support Level 6.08
3rd Support Level 5.90

See More

52-Week High 10.42
Fibonacci 61.8% 7.77
Fibonacci 50% 6.95
Last Price 6.45
Fibonacci 38.2% 6.13
52-Week Low 3.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.